The Pharma Data

OCTOBER 18, 2020

Dr. Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinical development for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

Drug Target Review

DECEMBER 13, 2024

7,8 The discovery of these biomarkers provides valuable insights into prognosis and disease progression, while also guiding the clinical development of new targeted immunotherapies. Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research. Discov Oncol. 2024;15(1):327. 2022;39(1):89-103.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

The Pharma Data

MAY 15, 2023

The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. About XinThera XinThera is a private biotechnology company whose mission is to develop best-in-class small molecule drugs to treat cancer and immunologic diseases.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

MARCH 1, 2022

” The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

OCTOBER 14, 2020

International Dial-in Number: (210) 874-7715. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Conference Call Information : Date : Thursday, November 5, 2020.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. Sinai Health Network.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

The Pharma Data

JANUARY 13, 2021

The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. International Immunol. (11):1583 The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. WO 2021/001458 A1. Structure.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 19, 2021

Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor. Qilian International – Jiuquan, China-based Qilian International holding Group Limited, a pharmaceutical and chemical products manufacturer, announced its IPO of 5 million ordinary shares at $5 per share on January 14.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

JANUARY 7, 2021

ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. FACP and all the employees at Oncoceutics in developing a therapy for patients for which there is no available treatment.”. scientific founder Wafik El-Deiry, M.D.,

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

The Pharma Data

JANUARY 19, 2021

The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Forward-Looking Statements. There can be no assurance that the Company will be able to complete the public offering on the anticipated terms, or at all.

Small Molecule 40

Small Molecule Clinical Development Treatment Disease 40

The Pharma Data

DECEMBER 15, 2020

Anokion is responsible for preclinical activities and Phase I clinical development of partnered programs, and Bristol Myers Squibb will fund subsequent trials and commercial activities at clinical proof-of-concept. Small Molecule Inhibitors. Oral, Small Molecules.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

The Pharma Data

JANUARY 3, 2021

Alternatively, the call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4787 (international) and referring to conference ID 5824089. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

New Drug Approvals

JANUARY 3, 2023

Adagrasib Formula C32H35ClFN7O2 cas 2326521-71-3 Mol weight 604.1174 Antineoplastic Disease Non-small cell lung cancer 2022/12/12 FDA APPROVED, KRAZATI (Mirati Therapeutics) MRTX-849 MRTX849 KRAS G12C inhibitor MRTX849 Adagrasib , sold under the brand name Krazati , is an anticancer medication used to treat non-small cell lung cancer. [1]

FDA 52

FDA Clinical Trials FDA Approval Treatment 52

The Pharma Data

OCTOBER 18, 2020

CG-806 is an oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor and is in Phase 1 clinical studies for the treatment of lymphoid and myeloid hematologic malignancies. This press release contains forward-looking statements within the meaning of Canadian and U.S.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

AUGUST 29, 2020

3,4 LNP023 is currently in clinical development for PNH and a number of renal conditions with complement system involvement where significant unmet needs exist, including IgA nephropathy, complement 3 glomerulopathy (C3G), atypical hemolytic uremic syndrome and membranous nephropathy. Blood 2019;134(Suppl 1):3517. Data on file. # # #.

Treatment 52

Treatment Disease Small Molecule Production 52

The Pharma Data

SEPTEMBER 15, 2020

In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval. Internal Medicine. These results were presented in August at the Digital International Liver Congress 2020. approval in 2021. mg/dL reduction for placebo.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Agency IQ

JULY 26, 2024

Postapproval manufacturing changes for biological products During clinical development or following a product’s approval , sponsors and/or manufacturers may identify the need for a change in the product, production process, quality controls, equipment, facilities, responsible personnel, or labeling. Any CMC changes (e.g.,

Biosimilars 40

Biosimilars Science FDA Production 40

Agency IQ

DECEMBER 11, 2023

So far in 2023, the Office has co-authored fifteen guidance documents—the majority of which were drafts—offering insight into the agency’s thinking on several key policy issues, such as clinical trial diversity and the accelerated approval pathway. AgencyIQ has identified several major themes in the FDA’s oncology work.

FDA 40

FDA Science Clinical Trials Trials 40

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Click here for available international numbers. Morgan Stanley and Goldman Sachs International are joint corporate brokers.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

DECEMBER 27, 2020

Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Tislelizumab is not approved for use outside of China. About BRUKINSA ® (zanubrutinib).

Production 52

Production Therapies Treatment Drugs 52

The Pharma Data

MAY 6, 2021

The IOC and International Paralympics Committee (IPC) have made it clear that vaccination is not mandatory in order for athletes to participate in the Olympic and Paralympic Games, and that any vaccination program must be conducted in full respect of national vaccination priorities.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 7, 2021

As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform.

Small Molecule 40

Small Molecule Clinical Development Production Science 40

The Pharma Data

NOVEMBER 22, 2020

The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 2184075. An archived replay of the webcast will be available via Cytokinetics’ website until December 7, 2020.

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

OCTOBER 26, 2020

V590 — a SARS-CoV-2 vaccine candidate in development in collaboration with the International AIDS Vaccine Initiative (IAVI) that uses a recombinant vesicular stomatitis virus (rVSV) platform, the same platform used for Merck’s approved Ebola Zaire virus vaccine, will enter Phase 1 development shortly.

Vaccine 40

Vaccine Trials Treatment Therapies 40

The Pharma Data

NOVEMBER 4, 2020

and Canada) or (484) 365-2865 (International) five minutes prior to the start time. Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). .

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

The Pharma Data

NOVEMBER 8, 2020

We have done this by both internal talent development as well as by external hires. At the end of August, Almirall announced the achievement of a milestone in its strategic collaboration with HitGen to develop a novel class of drugs. Several novel small molecule leads were the subject of this achievement.

Licensing 52

Licensing Licensing Production Marketing 52

The Pharma Data

SEPTEMBER 9, 2020

Our aim is to develop a safe and effective vaccine to contribute to bringing this pandemic to an end in Europe and across the world. Today’s decision is a further illustration of how collaboration and solidarity can help address a global health crisis as an international community,” said Ugur Sahin, M.D.,

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

OCTOBER 28, 2020

PIPELINE UPDATE: MOMENTUM IN OUR DYNAMIC R&D GROWTH ENGINE Takeda has built a world-class R&D engine leveraging our internal research capabilities, while also actively engaging with innovative ecosystems around the world to translate science into highly innovative medicines. billion to date. Press release , website ).

Therapies 40

Therapies Clinical Trials Pharmaceutical Companies Engineering 40

Drug Target Review

FEBRUARY 11, 2025

Addressing the long timelines and high costs of drug development is therefore critical for the advancement of medical innovation. Clinical development failure may be due to an inability to demonstrate efficacy or sufficient safety. Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59